Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HNRNPAB_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HNRNPAB_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HNRNPAB_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HNRNPAB_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HNRNPAB_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HNRNPAB_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HNRNPAB_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HNRNPAB_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HNRNPAB_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HNRNPAB_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HNRNPAB_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00018373 | Breast | Precancer | epithelial to mesenchymal transition | 19/1080 | 157/18723 | 1.78e-03 | 1.75e-02 | 19 |
GO:000183711 | Breast | IDC | epithelial to mesenchymal transition | 23/1434 | 157/18723 | 1.97e-03 | 1.88e-02 | 23 |
GO:000183721 | Breast | DCIS | epithelial to mesenchymal transition | 22/1390 | 157/18723 | 2.92e-03 | 2.50e-02 | 22 |
GO:00018374 | Cervix | CC | epithelial to mesenchymal transition | 31/2311 | 157/18723 | 5.25e-03 | 3.08e-02 | 31 |
GO:00487624 | Cervix | CC | mesenchymal cell differentiation | 42/2311 | 236/18723 | 9.12e-03 | 4.60e-02 | 42 |
GO:0048762 | Colorectum | MSS | mesenchymal cell differentiation | 59/3467 | 236/18723 | 7.79e-03 | 4.84e-02 | 59 |
GO:00487621 | Colorectum | FAP | mesenchymal cell differentiation | 52/2622 | 236/18723 | 5.08e-04 | 5.80e-03 | 52 |
GO:0001837 | Colorectum | FAP | epithelial to mesenchymal transition | 36/2622 | 157/18723 | 1.67e-03 | 1.47e-02 | 36 |
GO:0060485 | Colorectum | FAP | mesenchyme development | 59/2622 | 291/18723 | 1.94e-03 | 1.64e-02 | 59 |
GO:00487625 | Endometrium | AEH | mesenchymal cell differentiation | 46/2100 | 236/18723 | 1.27e-04 | 1.74e-03 | 46 |
GO:00604853 | Endometrium | AEH | mesenchyme development | 54/2100 | 291/18723 | 1.34e-04 | 1.83e-03 | 54 |
GO:00018375 | Endometrium | AEH | epithelial to mesenchymal transition | 33/2100 | 157/18723 | 2.64e-04 | 3.09e-03 | 33 |
GO:004876212 | Endometrium | EEC | mesenchymal cell differentiation | 47/2168 | 236/18723 | 1.35e-04 | 1.76e-03 | 47 |
GO:006048512 | Endometrium | EEC | mesenchyme development | 54/2168 | 291/18723 | 3.01e-04 | 3.37e-03 | 54 |
GO:000183712 | Endometrium | EEC | epithelial to mesenchymal transition | 33/2168 | 157/18723 | 4.71e-04 | 4.84e-03 | 33 |
GO:00018378 | Esophagus | ESCC | epithelial to mesenchymal transition | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
GO:00487628 | Esophagus | ESCC | mesenchymal cell differentiation | 133/8552 | 236/18723 | 5.94e-04 | 3.22e-03 | 133 |
GO:00604856 | Esophagus | ESCC | mesenchyme development | 156/8552 | 291/18723 | 3.76e-03 | 1.53e-02 | 156 |
GO:00018377 | Oral cavity | OSCC | epithelial to mesenchymal transition | 82/7305 | 157/18723 | 5.09e-04 | 2.98e-03 | 82 |
GO:00487627 | Oral cavity | OSCC | mesenchymal cell differentiation | 109/7305 | 236/18723 | 1.43e-02 | 4.69e-02 | 109 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HNRNPAB | SNV | Missense_Mutation | novel | c.622G>A | p.Val208Met | p.V208M | Q99729 | protein_coding | deleterious(0.01) | probably_damaging(0.921) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HNRNPAB | SNV | Missense_Mutation | rs199566621 | c.880N>A | p.Asp294Asn | p.D294N | Q99729 | protein_coding | tolerated(0.82) | possibly_damaging(0.807) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HNRNPAB | SNV | Missense_Mutation | | c.896G>T | p.Gly299Val | p.G299V | Q99729 | protein_coding | deleterious(0.02) | possibly_damaging(0.747) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HNRNPAB | SNV | Missense_Mutation | novel | c.242N>A | p.Thr81Asn | p.T81N | Q99729 | protein_coding | deleterious(0.01) | possibly_damaging(0.618) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HNRNPAB | SNV | Missense_Mutation | novel | c.507N>T | p.Lys169Asn | p.K169N | Q99729 | protein_coding | deleterious(0.03) | benign(0.062) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HNRNPAB | SNV | Missense_Mutation | novel | c.968N>A | p.Gly323Asp | p.G323D | Q99729 | protein_coding | deleterious(0) | possibly_damaging(0.856) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HNRNPAB | SNV | Missense_Mutation | rs528992480 | c.922N>A | p.Asp308Asn | p.D308N | Q99729 | protein_coding | tolerated(0.14) | benign(0.025) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
HNRNPAB | SNV | Missense_Mutation | novel | c.581N>T | p.Arg194Ile | p.R194I | Q99729 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
HNRNPAB | SNV | Missense_Mutation | rs146516910 | c.734N>A | p.Arg245His | p.R245H | Q99729 | protein_coding | tolerated(0.53) | benign(0.246) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HNRNPAB | insertion | Frame_Shift_Ins | novel | c.702_703insT | p.Tyr235LeufsTer79 | p.Y235Lfs*79 | Q99729 | protein_coding | | | TCGA-D1-A168-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |